Cardiovascular Clinical Studies

This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.

HRS study finds Frequent Coffee Consumption Lowers Chance of Arrhythmias. #HRS #HRS20 Heartrhythm20
News | EP Lab | May 28, 2020
May 28, 2020 – A recent study revealed that drinking a couple of cups of coffee per day does not lead to a greater risk...
TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, the...
WHO Database Shows Serious Health Impact of Hydroxychloroquine and Azithromycin Being Used to Treat COVID-19. #COVID19 #SARScov2 #Hydroxychloroquine
Feature | Coronavirus (COVID-19) | May 27, 2020
May 27, 2020 — Two of the front-line drugs being used to treat COVID-19 (SARS-CoV-2) patients are hydroxychloroquine...
Videos | HRS | May 22, 2020
Interview with Andrew D. Krahn, M.D., FHRS, head of the division of cardiology at St. Paul’s Hospital, and professor of...
SCAI Announces 2020 Late-breaking Clinical Studies, featured clinical research sessions. #SCAI2020
Feature | SCAI | May 21, 2020
May 21, 2020 — Here is the list of late-breaking study presentations and links to articles about each of them from the...
Left, the Melody pulmonary valve was the first transcatheter valve to be approved by the FDA in the United States a decade ago. Right, the Harmony transcatheter valve is in trials and is designed to treat patients with RVOT anomalies who develop severe PR typically when a pervious repair fails. Both valves are used to treat congenital heart defects. #SCAI #SCAI2020

Left, the Melody pulmonary valve was the first transcatheter valve to be approved by the FDA in the United States a decade ago. Right, the Harmony transcatheter valve is in trials and is designed to treat patients with RVOT anomalies who develop severe PR typically when a pervious repair fails. Both valves are used to treat congenital heart defects.

News | Congenital Heart | May 21, 2020
May 21, 2020 — Two late-breaking clinical trials on trans catheter valves to treat congenital heart disease were...
Rash on the skin of a child who has COVID-19 related multi-system inflammatory syndrome (MIS-C). Image copyright Damien Bonnet, M.D., Ph.D., courtesy of the American Heart Association. Coronavirus is linked with this Kawasaki-like inflammatory disease in children.

Rash on the skin of a child who has COVID-19 related multi-system inflammatory syndrome (MIS-C). The image is from  Damien Bonnet, M.D., Ph.D., Necker Hospital-Université, Paris, who was involved in a Circulation study published on MIS-C May 14. Image copyright Damien Bonnet, courtesy of the American Heart Association.

Feature | Coronavirus (COVID-19) | May 20, 2020 | Dave Fornell, Editor
A new, serious COVID-19 cardiovascular presentation emerged in late April and early May 2020 in the form of pediatric...
PREDICT-AF trial showed first time there is extensive extracellular matrix remodeling. #HRS2020 #Heartrhythm2020. Marilyn Fornell
News | Atrial Fibrillation | May 19, 2020
May 19, 2020 — Structural changes of the atrium may occur long before the onset of atrial fibrillation (AF), and the...
Results of the Atrial Fibrosis Predicts Recurrent Stroke Or New Atrial Fibrillation In Patients With Embolic Stroke Of Undetermined Source - A Multi-Center Study at HRS 2020. #HRS2020 #Heartrhythm2020,
News | Atrial Fibrillation | May 19, 2020
May 19, 2020 — Atrial disease has been implicated in embolic stroke of undetermined source (ESUS) and a late-breaking...
Mayo Clinic is using artificial intelligence EchoGo Core software from Ultromics to automatically analyize echocardiography images to assess the cardiac impact of COVID-19. The AI software is from Ultromics.

Mayo Clinic is using artificial intelligence EchoGo Core software from Ultromics to automatically analyize echocardiography images to assess the cardiac impact of COVID-19.

News | Coronavirus (COVID-19) | May 19, 2020
May 19, 2020 — A joint U.K.-U.S. research team is applying a pioneering artificial intelligence (AI) system to...
Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, or nil per os (NPO), as there are no current standardized fasting protocols, but the CHOWNOW study found patients do not need to fast and will have similar outcomes. #SCAI2020
Feature | Cath Lab | May 18, 2020
May 18, 2020 – Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, or...
ISCHEMIA Trial: Patients With Intermediate Left Main Coronary Disease Have Worse Cardiovascular Events. #SCAI2020
News | SCAI | May 17, 2020
May 17, 2020 – A new study shows that when compared with patients without intermediate left main coronary artery...
CD34+ Stem Cell Therapy Improved Quality of Life in Patients with Microvascular Dysfunction. #SCAI2020
News | May 17, 2020
May 17, 2020 – Trial results presented today revealed a promising therapy for patients experiencing angina due to...
Icosapent Ethyl (Vascepa) significantly Reduces Revascularizations in Statin Patients in the REDUCE-IT REVASC analyses presented as a late-breaking study at SCAI 2020. Photo by Dave Fornell

Icosapent Ethyl (Vascepa) significantly reduces revascularizations in statin patients based on data from the REDUCE-IT REVASC analyses, presented as a late-breaking study at SCAI 2020. Photo by Dave Fornell

News | Pharmaceuticals | May 17, 2020
May 17, 2020 – Patients with high lipid levels have an increased risk for ischemic events, despite statin therapy....
The Boston Scientific Synergy stent uses a unique abluminal, bioresorbable drug-carrier polymer that dissolves after the vessel wall has healed months after the stent is implanted. Stent polymers have been implicated in cases of late-stent thrombosis, which required patients with DES to stay on dual antiplatelet therapy (DAPT). This study looked at using the device as a way to shorten DAPT duration. #SCAI2020

The Boston Scientific Synergy stent uses a unique abluminal, bioresorbable drug-carrier polymer that dissolves after the vessel wall has healed months after the stent is implanted. Stent polymers have been implicated in cases of late-stent thrombosis, which required patients with DES to stay on dual antiplatelet therapy (DAPT). This study looked at using the device as a way to shorten DAPT duration.

News | Stents | May 17, 2020
May 17, 2020 – A new study sought to reveal whether drug-eluting stents (DES) coated with bioabsorbable polymer (BP)...